• TherapeuticsMD posted net income from continuing operations of $103,000 for first-quarter 2026, swinging from a loss a year earlier.
• License revenue rose 84.22% year over year to $724,000, driven primarily by the Mayne License Agreement.
• Total operating expenses fell 13.6% to $1.45 million, reflecting absence of a 2025 write-off and lower professional fees and share-based compensation.
• Cash and cash equivalents totaled $8.4 million at March 31, 2026.
• Company continued evaluating strategic alternatives, including potential acquisition, merger, business combination, or asset sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605121605BIZWIRE_USPR_____20260512_BW202804) on May 12, 2026, and is solely responsible for the information contained therein.